Aripiprazole for the treatment of refractory anxiety: impact on clinical outcomes, resilience and neuroendocrinologic parameters

Trial Profile

Aripiprazole for the treatment of refractory anxiety: impact on clinical outcomes, resilience and neuroendocrinologic parameters

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2009

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Generalised anxiety disorder; Panic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Aug 2009 Actual initiation date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top